TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04388501
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.
Study: NCT05125679
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered by subcutaneous injection.
Study: NCT06429007
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be initiated at 25% of the target dose (4 mg/kg administered twice daily, total daily dose 8 mg/kg) for three weeks. In the absence of adverse effects, metformin dose will be escalated to 50% of the target dose (8 mg/kg administered twice daily for a total daily dose of 16mg/kg) for remaining 3 weeks to minimize potential gastrointestinal upset at higher doses. Parents will be documenting adverse events and performing glucometer checks twice a day for 3 days post dose escalation.~Parents will then receive a 6-week supply of metformin at the target dose (16 mg/kg administered twice daily, total daily dose 32 mg/kg). Adverse events will be documented and glucometer checks will be performed twice a day for 3 days following dose escalation.
Study: NCT06260683
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given nicotine patches and nicotine lozenges
Study: NCT05705401
Drug: Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
Normalized name: chicken breast preparation
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
Study: NCT06122779
Drug: BMS-986435
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06472908
Drug: Colchicine 0.5 mg
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5 mg, one pill a day, oral intake
Study: NCT06472908
Drug: Colchicine 0.375 mg
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.375 mg, one pill a day, oral intake
Study: NCT05245084
Drug: CKD-386(3)
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06277024
Drug: Combination of Cardonizumab with Lenvatinib and SOX regimen
Normalized name: combinations of levothyroxine and liothyronine
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1: Conduct a ramp up test on the dosage of lenvatinib according to the traditional 3+3 design; Phase 2: 6 cycles of treatment with candenizumab+lenvatinib+SOX regimen (Q3W); For patients who have not progressed, they will enter the third stage of maintenance treatment.~Phase 3: Maintenance therapy with candenizumab, lenvatinib, and tigio (Q3W).
Study: NCT06341712
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.
Study: NCT04666610
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.
Study: NCT05925114
Drug: S-309309
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as oral capsules
Study: NCT06414720
Drug: Dienogest 2 MG
Normalized name: dienogest 2 MG
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
Study: NCT04484259
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
Study: NCT04484259
Drug: Ticagrelor plus aspirin
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
Study: NCT04484259
Drug: Clopidogrel with aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
Study: NCT05139017
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion 1000 mg/m\^2
Study: NCT05139017
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion 100 mg/m\^2
Study: NCT05139017
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion 90 mg/m\^2
Study: NCT05139017
Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.
Study: NCT06784999
Drug: methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2. Intravenous methadone of 0.2 mg/kg IBW up to a maximum dose of 20mg, rounded to the nearest milligram. The methadone will be given at the beginning of the case, prior to surgical incision. n=64)
Study: NCT04711824
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
Study: NCT04711824
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
Study: NCT06208150
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered as a SC injection.
Study: NCT06208150
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered orally.
Study: NCT06208150
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered as a SC injection.
Study: NCT06208150
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab will be administered intravenously.
Study: NCT06208150
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered either orally or intravenously.
Study: NCT06208150
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered as a SC injection.
Study: NCT05386914
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg of Sirolimus taken orally once a day for 4 weeks.
Study: NCT05784129
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered subcutaneously.
Study: NCT05125302
Drug: Ubrogepant
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05125302
Drug: Placebo-Matching Ubrogepant
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05543252
Drug: Minzasolmin (UCB0599)
Normalized name: Minzasolmin
DrugBank: Minzasolmin (DB18961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
Study: NCT05976763
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06118515
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
Study: NCT04711109
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given SC
Study: NCT05044819
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Cannabidiol solution 100 mg/mL
Study: NCT05004259
Drug: Daratumumab / Hyaluronidase Injection
Normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of daratumumab and hyaluronidase
Study: NCT05639972
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV will be administered every 8 hours as an inpatient for up to 3 doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Study: NCT05976243
Drug: Remibrutinib
Normalized name: Remibrutinib
DrugBank: Remibrutinib (DB16852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remibrutinib treated groups and arms
Study: NCT05796570
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nucleoside metabolic inhibitor, via IV infusion.
Study: NCT05796570
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
Study: NCT04829318
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine will be self-administered as nasal spray.
Study: NCT06393738
Drug: ARV-393
Normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles
Study: NCT04677530
Drug: JNJ-40411813
Normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-40411813 will be administered orally.
Study: NCT05057806
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 25MG will be administered orally once per day for 3 months
Study: NCT04773522
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered subcutaneously.
Study: NCT05488314
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib will be administered orally.
Study: NCT05488314
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered as IV infusion.
Study: NCT06385548
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.
Study: NCT06385548
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
Study: NCT05252988
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
Study: NCT05252988
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide orally.
Study: NCT05252988
Drug: Colesevelam
Normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam capsules orally, 2 times a day for the first month (28 days).
Study: NCT05492123
Drug: Nivolumab 40 mg in 4 ml Injection
Normalized name: nivolumab 40 MG in 4 ML Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
Study: NCT05492123
Drug: Ipilimumab 200 MG in 40 ML Injection
Normalized name: ipilimumab 200 MG in 40 ML Injection
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
Study: NCT04722146
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive teclistamab.
Study: NCT04722146
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive daratumumab.
Study: NCT04722146
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive pomalidomide.
Study: NCT04722146
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive lenalidomide.
Study: NCT04722146
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive bortezomib.
Study: NCT04722146
Drug: Nirogacestat
Normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive nirogacestat.
Study: NCT05455684
Drug: Aticaprant
Normalized name: Aticaprant
DrugBank: Aticaprant (DB12341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aticaprant will be administered orally as tablets.
Study: NCT06496373
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab
Study: NCT06624228
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Study participants will receive bimekizumab at pre-specified time points.
Study: NCT06620848
Drug: HRS-4642 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.
Study: NCT06620848
Drug: HRS-4642 and adebrelimab combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.
Study: NCT04630028
Drug: Ustekinumab Dose Based on BSA and Body Weight
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As per BSA and body weight Ustekinumab will be administered SC and IV.
Study: NCT03643367
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
Study: NCT04598477
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone tablets
Study: NCT06624228
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study participants will receive risankizumab at pre-specified time points.
Study: NCT00001123
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05167825
Drug: Macitentan
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan will be administered orally as a tablet.
Study: NCT04936308
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive guselkumab as SC injection.
Study: NCT05041842
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg orally twice daily
Study: NCT05041842
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
Study: NCT05041842
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly
Study: NCT05041842
Drug: Pertuzumab/ Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly
Study: NCT06107153
Drug: Insulin Glargine 100 UNT/ML Pen Injector [Lantus]
Normalized name: insulin glargine 100 UNT/ML Pen Injector [Lantus]
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.
Study: NCT06107153
Drug: Pioglitazone 30mg
Normalized name: GLIMEPIRIDE 2MG/PIOGLITAZONE 30MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30mg
Study: NCT04903197
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immune-modulatory agent that enhances activation of NK cells.
Study: NCT05268003
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05268003
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT04547166
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
Study: NCT00221481
Drug: divalproex or olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05063565
Drug: Durvalumab (Imfinzi) immunotherapy
Normalized name: durvalumab Injection [Imfinzi]
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met
Study: NCT05901649
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.